QuIET: Quenching neuoro-Inflammation through Engineered Tolerance
Neuroinflammation is the common thread linking the most devastating brain diseases of our time: Alzheimer's, multiple sclerosis, Parkinson's, and traumatic brain injury — yet no approved therapy directly targets it through immune tolerance. Instead, millions of patients receive broad immunosuppressants that weaken the entire immune system while failing to reach the compartmentalized inflammation behind the blood-brain barrier that drives neuronal death, demyelination, and cognitive decline. This is not a gap; it is a failure of the current therapeutic paradigm. In Phase I, SNC demonstrated engineered immune tolerance; in Phase II, SNC will develop a more precise, clinically validated version of that technology to target the brain inflammation that current drugs cannot reach.